A Father’s Gift Honors His Son’s Achievements
“I’ve been inspired by Paul’s remarkable courage and perseverance to not let his glaucoma keep him from leading a full life,” says his father.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
“I’ve been inspired by Paul’s remarkable courage and perseverance to not let his glaucoma keep him from leading a full life,” says his father.
Cataracts are like wrinkles — everyone gets them when they get older. When people with glaucoma get cataracts, it’s the perfect opportunity to treat both problems at once.
“We are thrilled and honored to have Nancy join our Board of Directors,” said Andrew G. Iwach, MD, Chair of the Glaucoma Research Foundation Board of Directors.
Igor Leal is a talented singer-songwriter living with glaucoma.
In this “Questions and Answers” article, learn about new glaucoma medications available in 2019, how they’re different from existing treatments, and their potential side effects.
Every day, glaucoma researchers work to better understand and find safer, more effective ways to treat this debilitating disease.
Stem cell therapies are getting headlines for their potential to cure diseases, including those that affect vision. But an important message is missing: stem cell therapies are not yet proven to be safe and effective for your eyes.
The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop for patients with open-angle glaucoma, Aerie Pharmaceuticals announced in a press release this week.
The published UK study suggests Selective Laser Trabeculoplasty should become the principal method for treating patients with glaucoma.
Dr. Di Polo’s laboratory investigated the hypothesis that insulin can improve the survival and function of injured retinal ganglion cells and may be viable as an innovative glaucoma treatment.
In normal-tension glaucoma, the optic nerve gets damaged even though the eye pressure is within a normal range.
For the first time, thanks to improvements in how we measure the disease, researchers are studying and testing new therapeutic candidates for neuroprotection, neuroenhancement, and visual restoration.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.